Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.56 |
| ▸ | GABRP | O00591 | 2/20 | 0.56 |
| ▸ | GABRD | O14764 | 2/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.56 |
| ▸ | GABRE | P78334 | 2/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7033035 | 0.98 | AR (0.58) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11932816 | 0.91 | AR (0.59) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7032972 | 0.89 | AR (0.68) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7033021 | 0.88 | AR (0.63) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11932859 | 0.87 | AR (0.56) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7031419 | 0.87 | AR (0.69) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11932814 | 0.86 | AR (0.54) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11892392 | 0.85 | AR (0.58) | AR | |
| SCHEMBL11893307 | 0.84 | AR (0.69) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11932820 | 0.84 | AR (0.56) | ARGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650359-B2 | Modulators of resistant androgen receptor | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170087132-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2017-03-30 | — | — | US | disclosed |
| US-9517229-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160257666-A1 | MODULATORS OF RESISTANT ANDROGEN RECEPTOR | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-09-08 | — | — | US | disclosed |
| US-9365542-B2 | Modulators of resistant androgen receptor | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274693-A1 | MODULATORS OF RESISTANT ANDROGEN RECEPTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-01 | — | — | US | disclosed |
| US-20150265587-A1 | ANDROGEN RECEPTOR VARIANTS AND METHODS FOR MAKING AND USING | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-09-24 | — | — | US | disclosed |
| US-9126941-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | HOWARD HUGHES MEDICAL INSTITUTE | 2015-04-23 | — | — | US | disclosed |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| US-8658681-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-8648105-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140031409-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | SANTARIS PHARMA A/S (DK) | 2014-01-30 | — | — | US | disclosed |
| US-8450290-B2 | Methods for treating androgen receptor dependent disorders including cancers | ENZON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120190718-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-26 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | ENZON PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265587-A1 | ANDROGEN RECEPTOR VARIANTS AND METHODS FOR MAKING AND USING | AR, NR5A1, NR3C2 | AR 1/4885GABRP 2507/4885GABRD 2427/4885 |
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | AR, ESRRB, ESRRA | AR 1/4885GABRP 820/4885GABRD 277/4885 |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | AR 113/4885GABRP 4700/4885GABRD 3973/4885 |
| US-20140031409-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | AR, ESRRB, ESRRA | AR 1/4885GABRP 820/4885GABRD 277/4885 |
| US-20170087132-A1 | Treatment of Breast Cancer | BRCA1, MKI67, BAX | AR 2292/4885GABRP 2593/4885GABRD 3792/4885 |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20160257666-A1 | MODULATORS OF RESISTANT ANDROGEN RECEPTOR | AR, NR5A1, ESRRA | AR 1/4885GABRP 256/4885GABRD 179/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | AR 2166/4885GABRP 2459/4885GABRD 3707/4885 |
| US-20120190718-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | AR, SHBG, PTMS | AR 1/4885GABRP 3664/4885GABRD 2624/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | AR 11/4885GABRP 4859/4885GABRD 4634/4885 |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | AR, SHBG, PTMS | AR 1/4885GABRP 3664/4885GABRD 2624/4885 |
| US-20150274693-A1 | MODULATORS OF RESISTANT ANDROGEN RECEPTOR | AR, NR5A1, ESRRA | AR 1/4885GABRP 396/4885GABRD 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.